Related Experiment Video

Updated: Apr 24, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

7.2K

Increasing Volume but Decreasing Mortality of Hospitalized Hepatitis C Patients in the United States, 2005 to 2011

Ruihong Luo1, Alan Greenberg, Christian D Stone

  • 1*Department of Internal Medicine ‡Section of Gastroenterology and Hepatology, University of Nevada School of Medicine †Infectious Disease Specialists, University Medical Center of Southern Nevada, Las Vegas, NV.

Journal of Clinical Gastroenterology
|September 10, 2014
PubMed

Insights

Hospitalizations for hepatitis C increased from 2005 to 2011, with rising costs despite declining mortality. A new model can predict patient outcomes and improve care.

Area of Science:

  • Hepatology
  • Public Health
  • Health Economics

Background:

  • Hepatitis C virus infection frequently leads to hospitalization for advanced liver disease and complications.
  • These hospitalizations carry significant financial burdens and mortality risks.

Purpose of the Study:

  • To examine recent trends in the economic burden and patient outcomes for hepatitis C hospitalizations in the United States.
  • To identify key risk factors for in-hospital mortality.

Main Methods:

  • Analysis of Nationwide Inpatient Sample data from 2005 to 2011 for hepatitis C-associated hospitalizations.
  • Evaluation of in-hospital mortality, hospital service utilization, and patient demographics/clinical features.
  • Development of a prognostic model to predict in-hospital survival using identified risk factors.

Main Results:

  • Identified 607,279 hepatitis C hospitalizations; annual volume rose 28.8% over 7 years.
  • In-hospital mortality decreased from 8.2% to 6.4%, but inflation-adjusted charges increased by 33.3%.
  • Acute respiratory failure, septicemia, renal failure, and acute liver failure were major mortality predictors; a risk-adjusted model achieved 89.2% accuracy.

Conclusions:

  • Hepatitis C hospitalizations increased in volume and cost between 2005 and 2011, despite reduced mortality.
  • A developed risk-adjusted model can effectively predict in-hospital mortality for hepatitis C patients.
  • The model offers potential for improving patient outcomes and resource management.
Abstract

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.5K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
74
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
377
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.7K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
17
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
377